公开(公告)号：US20150166652A1

公开(公告)日：2015-06-18

申请号：US14633294

申请日：2015-02-27

Applicant: UCB PHARMA, S.A.

Inventor： MARK ELLIS ,  DAVID PAUL HUMPHREYS

IPC: C07K16/24 ,  C12N1/20

CPC classification number: C07K16/241 ,  C07K14/245 ,  C07K2317/14 ,  C12N1/20

Abstract: The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell.

Abstract translation: 本发明提供重组革兰氏阴性细菌细胞，其特征在于该细胞包含编码DsbC的重组多核苷酸，与野生型细胞相比具有降低的Tsp蛋白活性。

公开(公告)号：US09034600B2

公开(公告)日：2015-05-19

申请号：US14074880

申请日：2013-11-08

Applicant: UCB PHARMA S.A.

Inventor： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC: C12N15/09 ,  C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/33 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。

公开(公告)号：US20140080134A1

公开(公告)日：2014-03-20

申请号：US14084047

申请日：2013-11-19

Applicant: UCB PHARMA S.A.

Inventor： ADAM SAMUEL PLATT ,  STEPHEN EDWARD RAPECKI ,  MARA FORTUNATO ,  DAVID ROBERT RAINEY ,  JON LEIGH RUNDLE ,  PAUL ALFRED SMITH ,  GILLIAN SAIRFULL WATT

IPC: C12Q1/68 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/6869 ,  G01N33/6893

Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.

Abstract translation: 本发明提供脂质运载蛋白2（LCN2）作为IL-17介导的疾病的生物标志物并用于监测患者对抗IL-17治疗的反应的用途。

公开(公告)号：US20140065674A1

公开(公告)日：2014-03-06

申请号：US14074880

申请日：2013-11-08

Applicant: UCB PHARMA S.A.

Inventor： RALPH ADAMS ,  TERENCE SEWARD BAKER ,  ALASTAIR DAVID GRIFFITHS LAWSON

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/33 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。

公开(公告)号：US20130245229A1

公开(公告)日：2013-09-19

申请号：US13709055

申请日：2012-12-09

Applicant: UCB PHARMA S.A.

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki ,  Simon Peter Tickle

IPC: C07K16/46 ,  A61K47/48

CPC classification number: C07K16/244 ,  A61K47/48215 ,  A61K47/60 ,  A61K2039/505 ,  C07K16/464 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.

公开(公告)号：US20130150573A1

公开(公告)日：2013-06-13

申请号：US13760788

申请日：2013-02-06

Applicant: UCB Pharma S.A.

Inventor： Clive Martin Hutchings ,  Sarah Catherine Archibald ,  Daniel Christopher Brookings ,  Jeremy Martin Davis ,  James Andrew Johnson ,  Barry John Langham ,  Judi Charlotte Neuss

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: Novel processes for the preparation of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety and intermediates thereto are provided. The compounds prepared by the present processes may be useful, for example, as selective inhibitors of human MEK (MAPKK) enzymes, and are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions. The present processes may offer improved yields, chemical or stereochemical purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.

Abstract translation: 提供了通过取代的苯胺基部分在2-位上被取代的噻吩并[2,3-b]吡啶衍生物的制备方法及其中间体。 通过本方法制备的化合物可用作例如人MEK（MAPKK）酶的选择性抑制剂，因此在医学中有益，例如在治疗炎症，自身免疫，心血管，增殖（包括肿瘤） 和伤害感受条件。 本方法可以提供改进的产率，化学或立体化学纯度，中间体和最终产物的制备和/或分离的容易程度，以及更具有工业上有用的反应条件和可加工性。

公开(公告)号：US12091450B2

公开(公告)日：2024-09-17

申请号：US16717671

申请日：2019-12-17

Applicant: UCB PHARMA S.A.

Inventor： David Paul Humphreys ,  Ralph Adams ,  James Heads ,  Shirley Jane Peters

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/24 ,  C12P21/08

CPC classification number: C07K16/24 ,  A61K39/39591 ,  C07K16/00 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/94

Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.

公开(公告)号：US11702468B2

公开(公告)日：2023-07-18

申请号：US16554510

申请日：2019-08-28

Applicant: UCB Pharma, S.A.

Inventor： David G. Winkler ,  Jiye Shi ,  John Latham

IPC: G01N33/68 ,  G01N33/50 ,  G01N33/577 ,  C07K16/22 ,  C07K14/51 ,  C07K16/18 ,  A61K47/64 ,  C07K14/475

CPC classification number: C07K16/22 ,  A61K47/643 ,  A61K47/646 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  G01N33/6854 ,  C07K2317/76 ,  G01N33/50 ,  G01N33/577 ,  G01N33/68 ,  G01N33/6863 ,  G01N2333/4704

Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

公开(公告)号：US20220289832A1

公开(公告)日：2022-09-15

申请号：US17750444

申请日：2022-05-23

Applicant: UCB PHARMA, S.A.

Inventor： MARIANGELA SPITALI ,  JONATHAN SYMMONS ,  RICHARD WHITCOMBE ,  MARK ROBERT PEARCE-HIGGINS

IPC: C07K16/24 ,  C07K1/36 ,  C07K1/18

Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.

公开(公告)号：US11427650B2

公开(公告)日：2022-08-30

申请号：US16124650

申请日：2019-01-21

Applicant: UCB PHARMA S.A.

Inventor： David Paul Humphreys ,  Emma Dave ,  Laura Griffin ,  Sam Philip Heywood

IPC: C07K16/46 ,  C07K16/00 ,  C07K16/18 ,  C07K16/24

Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.